SCHEMBL10193646

SCHEMBL10193646

Fc1ccc(C(F)(F)F)cc1-c1cc(-c2c[nH]c3ccccc23)c2cccnc2n1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDK5 Q00535 2/20 0.45
CDK5R1 Q15078 2/20 0.45
KIF11 P52732 1/20 0.44
DYRK1A Q13627 3/20 0.43
GSK3B P49841 3/20 0.43
PRKCB P05771 1/20 0.39
MPL P40238 1/20 0.39
CLK1 P49759 1/20 0.39
MAP3K14 Q99558 1/20 0.39
ABCG2 Q9UNQ0 1/20 0.38
PIM1 P11309 1/20 0.38
SLC40A1 Q9NP59 1/20 0.37
TDO2 P48775 1/20 0.37
ALOX5 P09917 1/20 0.37
ELANE P08246 1/20 0.37
ABL1 P00519 1/20 0.37
EGFR P00533 1/20 0.37
BCR P11274 1/20 0.37
SRC P12931 1/20 0.37
PRKCA P17252 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14877111 0.90 IKBKE (0.49) CDK5CDK5R1KIF11DYRK1AGSK3B
SCHEMBL14877206 0.88 CDC7 (0.46) CDK5CDK5R1DYRK1AGSK3BPIM1
SCHEMBL247275 0.81 MPL (0.44) KIF11MPLABCG2SLC40A1
SCHEMBL12441314 0.78 MPL (0.44) KIF11MPLABCG2SLC40A1
SCHEMBL12424715 0.78 MPL (0.44) KIF11MPLABCG2SLC40A1
SCHEMBL3386631 0.77 CDC7 (0.47) CDK5CDK5R1DYRK1AGSK3BPIM1
SCHEMBL3390279 0.77 RIPK1 (0.48) KIF11DYRK1AGSK3BMPLABCG2
SCHEMBL246600 0.77 MPL (0.42) KIF11MPLABCG2SLC40A1
SCHEMBL3378612 0.76 TGFBR1 (0.52) DYRK1AGSK3BPIM1ELANE
SCHEMBL2298429 0.75 TRPV1 (0.52) MPLABCG2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2585461-B1 2,4-DIARYL-SUBSTITUTED [1,8]NAPHTHYRIDINES AS KINASE INHIBITORS FOR USE AGAINST CANCER MERCK PATENT GMBH (DE) 2020-02-26 EP disclosed
US-8791113-B2 2,4-diaryl-substituted [1,8] naphthyridines as kinase inhibitors for use against cancer MERCK PATENT GMBH (DE) 2014-07-29 US disclosed
US-20130102603-A1 2,4-DIARYL - SUBSTITUTED [1,8] NAPHTHYRIDINES AS KINASE INHIBITORS FOR USE AGAINST CANCER MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2013-04-25 US disclosed
WO-2012000595-A1 2,4- DIARYL - SUBSTITUTED [1,8] NAPHTHYRIDINES AS KINASE INHIBITORS FOR USE AGAINST CANCER MERCK PATENT GMBH (DE) 2012-01-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130102603-A1 2,4-DIARYL - SUBSTITUTED [1,8] NAPHTHYRIDINES AS KINASE INHIBITORS FOR USE AGAINST CANCER TGFBR1, TAB1, TGFBR2 CDK5 200/4885CDK5R1 174/4885KIF11 3422/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.